Release
Immediate Release

DOD and HHS Partner to Award $119 Million Contract to Hologic, Inc. to Increase Domestic Production Capacity of COVID-19 Diagnostic Tests

Oct. 30, 2020

On October 30, 2020, the Department of Defense (DOD), in coordination with the Department of Health and Human Services, awarded Hologic, Inc. a $119 million contract to expand domestic production, increasing testing for COVID-19.

This industrial base expansion effort will enable Hologic, Inc. to expand production capacity for COVID-19 tests and test consumables in supplier’s facilities in Wisconsin, Maine, and California, increasing capacity to 13 million tests per month by January 2022. 

Hologic, with support from BARDA funding, developed the Panther Fusion SARS-CoV-2 Assay and the Aptima SARS-CoV-2 Assay, both of which were granted Food and Drug Administration (FDA) Emergency Use Authorization earlier this year. Over 1,000 tests per day, taking approximately three hours each, can be performed on over 1,100 of Hologic’s Panther and Panther Fusion diagnostic platforms distributed across the U.S.

The DOD’s Defense Assisted Acquisition (DA2) Cell led this effort in coordination with the Department of the Air Force’s Acquisition COVID-19 Task Force (DAF ACT) and the Biomedical Advanced Research and Development Authority (BARDA) within HHS. This effort was funded through the Health Care Enhancement Act (HCEA), to support domestic industrial base expansion for critical medical resources.